2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
6
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Hyperinsulinism
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Filgrastim
20
Etoposide
20
Ifosfamide
19
Cyclophosphamide
18
Vincristine
13
Radiotherapy
13
Doxorubicin
13
Peripheral Blood Stem Cell Transplantation
12
Melphalan
12
Carboplatin
10
Busulfan
9
Topotecan
8
Temozolomide
8
Magnetic Resonance Spectroscopy
8
X-Rays
6
Thiotepa
6
Phantoms, Imaging
6
Irinotecan
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
5
trioctyl phosphine oxide
4
Mesna
4
Docetaxel
4
Dactinomycin
4
temsirolimus
3
etoposide phosphate
3
cixutumumab
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled